Medical imaging AI software developer Subtle Medical has raised close to $10 million in a Series B+ funding round.
Investors include existing shareholders such as Fusion Fund, EnvisionX Capital, BRV Capital, Ignite Innovation, and Samsung Ventures, according to the company. With the new investment, Subtle said it plans to accelerate U.S. and global sales initiatives and expedite the launch of its new AI-driven products.
Also this month, Subtle received U.S. Food and Drug Administration clearance for its AI software that uses deep learning to generate synthetic short-tau inversion-recovery (STIR) images from already-acquired MRI T1- and T2-weighted contrast images.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
